Punto Health secures €2.3 million seed round to expand AI-driven dementia care platform

The round was co-led by Shilling VC and Plus Partners, with additional backing from Exceptional Ventures, Heartfelt, Fondo Bolsa Social, and ABAC Nest.

(L-R) Anna Muñoz-Farré, Co-founder & CEO at Punto Health; and Jack Eckersley, Co-founder & CTO at Punto Health | Image source: puntohealth.com
WT default author logo
Women's Tabloid News Desk

London-based healthtech startup Punto Health has raised €2.3 million in seed funding to support the development and rollout of its AI-powered dementia care platform across the UK and Spain. The round was co-led by Shilling VC and Plus Partners, with additional backing from Exceptional Ventures, Heartfelt, Fondo Bolsa Social, and ABAC Nest.

Founded in 2023 by engineers Anna Muñoz-Farré and Jack Eckersley, Punto Health focuses on early detection and personalised support for people experiencing dementia and cognitive decline. The company plans to use the new funding to speed up product development and expand its commercial presence in key European markets.

Punto Health’s platform brings together patients, carers and clinicians through three connected products. PuntoTest is an AI-powered, speech-based digital assessment designed to identify signs of cognitive impairment. PuntoCare operates as a companion app, offering personalised care plans, cognitive exercises, nutrition guidance, symptom monitoring and broader wellbeing support. For healthcare professionals, PuntoClinic provides a dashboard that brings together patient-reported outcomes alongside biomarker data.

In Spain, PuntoTest has already been trialled in ten pharmacies across Barcelona, involving more than 1,500 participants aged 50 and above. The wider platform is currently being piloted with North London NHS Foundation Trust, NHS Oxleas Foundation Trust, and several hospitals in Barcelona. Punto Health said it is supporting more than 200 users aged between 60 and 90, who have collectively completed over 30,000 activities on the platform.

Dementia has a disproportionate impact on women. Women tend to live longer than men, making age-related cognitive decline more likely, while hormonal changes linked to menopause may also increase vulnerability. In addition, women provide around two-thirds of unpaid dementia care.

The platform has been co-designed and clinically validated in collaboration with Ace Alzheimer Centre Barcelona. The latest seed funding follows a €718,500 pre-seed investment secured earlier by the company.

Share:

Related Insights

Swedfund invests in MSME growth and climate action in Vietnam

London’s Ankar raises $20 million in series A led by Atomico to scale AI patent platform

IceCure expects record North America fourth quarter sales following FDA clearance of ProSense Cryoablation

Copenhagen startup NobodyWho raises €2 million to power on-device AI models

GENNVAX breaks ground on $150 million vaccine plant set to be region’s largest

Molly Sims’ YSE Beauty secures $15 million series A investment led by Silas Capital

Atlantic 10 conference announces multi-year partnership with OrthoVirginia for Women’s Basketball Championship

Accenture and Palantir deepen global partnership to accelerate enterprise AI transformation